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Abstract
Purpose Clonidine may help prevent cardiac complications
in patients undergoing non-cardiac surgery and receiving
chronic beta-blocker therapy. We conducted a multicentre
pilot randomized trial to estimate recruitment rates for a full-
scale trial and to assess the safety and tolerability of combining
clonidine with chronic beta-blockade.
Methods Patients who were at elevated perioperative
cardiac risk, receiving chronic beta-blockade, and scheduled
for major non-cardiac surgery were recruited in a blinded
(participants, clinicians, outcome assessors) placebo-
controlled randomized trial at three Canadian hospitals.
Participants were randomized to clonidine (0.2 mg oral tablet
one hour before surgery, plus 0.2 mgday-1 transdermal patch
placed one hour before surgery and removed four days after
surgery or hospital discharge, whichever came first) or
matching placebo. Feasibility was evaluated based on
recruitment rates, with each centre being required to recruit
50 participants within 12-18 months. Additionally, we
reviewed study drug withdrawals and safety outcomes,
including clinically significant hypotension or bradycardia.
Results Eighty-two of the 168 participants were
randomized to receive clonidine and 86 to receive
placebo. The average time to recruit 50 participants at
each centre was 14.3 months. Six patients (7%) withdrew
from clonidine, while four (5%) withdrew from placebo.
Based on qualitative review, there were no major safety
concerns related to clonidine. There was a moderate
overall rate of cardiac morbidity, with 18 participants
(11%) suffering postoperative myocardial infarction.
Author Contributions Duminda Wijeysundera, Peter Choi, Neal
Badner, Penelope Brasher, Diego Delgado, and W. Scott Beattie
contributed to the conception and design of the study. Duminda
Wijeysundera, Peter Choi, Neal Badner, George Dresser, and W.
Scott Beattie contributed to the conduct of the study. Duminda
Wijeysundera, Penelope Brasher, and W. Scott Beattie contributed to
the analysis of the data, and all authors contributed to its
interpretation. Duminda Wijeysundera drafted the manuscript, and all
authors revised it critically for important intellectual content.
Duminda Wijeysundera, Peter Choi, and Neal Badner are responsible
for archiving the study files.
Electronic supplementary material The online version of this
article (doi:10.1007/s12630-014-0226-6) contains supplementary
material, which is available to authorized users.
D. N. Wijeysundera, MD, PhD (&)  W. S. Beattie, MD, PhD
Department of Anesthesia, Toronto General Hospital and
University of Toronto, Eaton Wing 3-450,
200 Elizabeth Street, Toronto, ON M5G 2C4, Canada
e-mail: d.wijeysundera@utoronto.ca
D. N. Wijeysundera, MD, PhD
Li Ka Shing Knowledge Institute of St. Michael’s Hospital,
Toronto, ON, Canada
P. T. Choi, MD  N. H. Badner, MD
Department of Anesthesiology, Pharmacology & Therapeutics,
University of British Columbia, Vancouver, BC, Canada
P. T. Choi, MD  P. M. Brasher, PhD
Centre for Clinical Epidemiology and Evaluation, Vancouver
Coastal Health Research Institute, Vancouver, BC, Canada
P. T. Choi, MD
Department of Anesthesiology and Perioperative Care,
Vancouver Acute, Vancouver, BC, Canada
N. H. Badner, MD
Department of Anesthesia and Perioperative Medicine,
University of British Columbia, Kelowna, BC, Canada
123
Can J Anesth/J Can Anesth (2014) 61:995–1003
DOI 10.1007/s12630-014-0226-6
Conclusion This pilot randomized trial confirmed the
feasibility, safety, and tolerability of a full-scale trial of oral
and transdermal clonidine for reducing the risk of cardiac
complications during non-cardiac surgery. This trial was
registered at www.clinicaltrials.gov: NCT00335582.
Re´sume´
Objectif La clonidine pourrait contribuer a` pre´venir les
complications cardiaques chez des patients subissant une
chirurgie non cardiaque et recevant un traitement
chronique par beˆta-bloqueurs. Nous avons dirige´ une
e´tude pilote randomise´e, multicentrique, pour estimer les
vitesses de recrutement d’une e´tude de´finitive et pour
e´valuer l’innocuite´ et la tole´rabilite´ d’une association de la
clonidine avec des beˆta-bloqueurs administre´s en
traitement chronique.
Me´thodes Des patients qui pre´sentaient un risque
cardiaque pe´riope´ratoire e´leve´, recevaient un traitement
chronique par beˆta-bloqueurs et devaient subir une
intervention chirurgicale majeure non cardiaque
programme´e ont e´te´ recrute´s dans une e´tude randomise´e
en insu (participants, cliniciens, e´valuateurs de
l’aboutissement), controˆle´e par placebo, dans trois
hoˆpitaux canadiens. Les participants ont e´te´ randomise´s
pour recevoir de la clonidine (un comprime´ de 0,2 mg per
os une heure avant l’ope´ration et 0,2 mgjour-1 en timbre
e´pidermique place´ une heure avant l’ope´ration et retire´
quatre jours plus tard ou au moment du conge´ de l’hoˆpital,
selon ce qui survenait en premier) ou un placebo
correspondant. La faisabilite´ a e´te´ e´value´e en fonction
des vitesses de recrutement, chaque centre devant recruter
50 participants dans un de´lai de 12 a` 18 mois. De plus,
nous avons analyse´ les arreˆts pre´mature´s du traitement
e´tudie´ et les re´sultats d’innocuite´, y compris les e´pisodes
cliniquement significatifs d’hypotension ou de bradycardie.
Re´sultats Quatre-vingt-deux des 168 participants ont e´te´
randomise´s dans le groupe recevant la clonidine et 86 dans
le groupe recevant le placebo. Le de´lai moyen de
recrutement des 50 participants dans chaque centre a e´te´
de 14,3 mois. Six patients (7 %) ont e´te´ retire´s du groupe
clonidine et quatre patients (5 %) ont e´te´ retire´s du groupe
placebo. Sur le plan qualitatif, l’analyse n’a releve´ aucun
proble`me majeur d’innocuite´ lie´ a` la clonidine. Il y a eu un
taux global mode´re´ de morbidite´ cardiaque,
18 participants (11 %) souffrant d’infarctus du myocarde
postope´ratoire.
Conclusion Cette e´tude pilote randomise´e a confirme´ la
faisabilite´, l’innocuite´ et la tole´rabilite´ d’une e´tude a`
grande e´chelle de l’administration orale et transdermique
de la clonidine sur la re´duction du risque de complications
cardiaques au cours d’une chirurgie non cardiaque. Cette
e´tude a e´te´ enregistre´e sur le site www.clinicaltrials.gov:
NCT00335582.
Cardiac complications are an important concern for patients
undergoing major non-cardiac surgery. Significant
myocardial injury occurs after 8% of such procedures1 and
leads to increased short- and long-term mortality.1,2 While
beta-blockers showed initial promise for preventing these
complications,3 these benefits may be offset by increased risks
of hypotension, stroke, and death.4
Beta-blockers likely prevent myocardial infarction (MI)
through an attenuation of perioperative hypertension and
tachycardia, which in turns helps preserve the balance
between myocardial oxygen supply and demand. Clonidine
is an alternative drug that may act along similar
mechanisms. Clonidine and other alpha-2 adrenergic
agonists inhibit central sympathetic outflow and thereby
attenuate perioperative hemodynamic abnormalities.5-8 In
previous systematic reviews,9,10 we found that alpha-2
adrenergic agonists may help prevent perioperative
mortality and MI. Clonidine also has other benefits,
including analgesia and anxiolysis without associated
respiratory depression.11 Furthermore, it has a favourable
pharmacokinetic profile. It is available in a transdermal
preparation that can be administered easily to post-surgical
patients who are unable to consume oral medications.12
Definitive evidence that clonidine prevents major
cardiac complications after non-cardiac surgery will
entail a large randomized controlled trial (RCT) with
sufficient statistical power to detect plausible moderate-
sized treatment effects. When assessing the feasibility of
such a trial, it is important to consider whether clonidine
can be administered in combination with chronic beta-
blocker therapy. Approximately 20-40% of patients
undergoing major non-cardiac surgery receive chronic
beta-blocker therapy.13,14 Such individuals may stand to
benefit from clonidine since they remain at elevated
perioperative cardiac risk.13 We therefore conducted the
Evaluating Perioperative Ischemia reduction with
Clonidine (EPIC) study, a multicentre pilot RCT of
clonidine in patients who were at intermediate- to high-
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risk of cardiac complications, receiving chronic beta-
blockade, and scheduled to undergo major non-cardiac
surgery. Our objectives were to estimate recruitment rates
for a full-scale RCT and to assess the safety and tolerability
of combining clonidine with chronic beta-blockade.
Recruitment would be considered successful if each




Potential participants were recruited in the preoperative
assessment clinics of the Toronto General Hospital (Toronto,
ON, Canada), Vancouver General Hospital (Vancouver, BC,
Canada), and Victoria Hospital (London, ON, Canada).
Eligibility criteria for participants included age 45 yr or
older, considered at intermediate- to high-risk of cardiac
complications, scheduled to undergo elective non-cardiac
surgery with an expected postoperative hospital length of
stay of at least 48 hr for medical reasons, and receiving oral
beta-blocker therapy for at least 30 days before surgery.
Patients were deemed at intermediate- to high-risk of cardiac
complications if they were undergoing major vascular surgery,
intermediate-risk surgery (i.e., intraperitoneal, intrathoracic,
carotid endarterectomy, major orthopedic, radical
prostatectomy, or head-and-neck procedures)15 with at least
one risk factor, or other surgery with at least two clinical risk
factors. The risk factors of interest were coronary artery
disease, heart failure, cerebrovascular disease, diabetes
mellitus, peripheral arterial disease, age 70 yr or older, and
estimated glomerular filtration rate B 60 mLmin-1.16
Exclusion criteria were pre-existing use of alpha-2 agonists,
prior adverse reaction to alpha-2 agonists, decompensated heart
failure, known left ventricular ejection fraction B 40%, systolic
blood pressure B 90 mmHg, known clinically significant aortic
stenosis, and concomitant life-threatening disease likely to
limit life expectancy to B 30 days. Patients, clinicians, data
collectors, and outcome adjudicators were blinded to treatment
assignment. This trial was approved by Health Canada as well
as the Research Ethics Boards of the University Health
Network (May 2005), London Health Sciences Centre
(December 2006), and University of British Columbia
(January 2007). All participants provided informed consent.
Randomization
The research pharmacy at Toronto General Hospital
prepared a computer-generated randomization schedule
employing permuted blocks of varying size with
stratification by hospital. Site-specific randomization lists
were forwarded to the research pharmacies at the
participating hospitals. To ensure concealment of treatment
allocation, randomization lists were available only to the
research pharmacists. On the morning of surgery, a research
pharmacist prepared the study drugs according to the
randomization list and sent the study drugs to the
preoperative holding area.
Interventions
Participants in the intervention arm received clonidine as a
0.2 mg oral tablet (Apo-Clonidine, Apotex Inc., Weston,
ON, Canada) and a transdermal patch (Catapres-TTS-2,
Boehringer Ingelheim Inc., Ridgefield, CT, USA) one hour
before surgery. These patches, which provided a
continuous delivery of 0.2 mgday-1, were removed on
postoperative day four or hospital discharge (whichever
occurred earlier). Participants in the placebo arm received
matching oral placebo tablets and inert patches. The
protocol was adapted from previous regimens that
reduced plasma catecholamine levels and myocardial
ischemia in surgical patients without causing adverse
hemodynamic effects.5,12 It also ensured that participants
received clonidine during the 72-hr postoperative period
during which perioperative MI generally occurs.17
Perioperative management
Participants received their usual dose of oral beta-blocker
on the morning of surgery and resumed their normal
regimen as soon as they could consume tablets orally.
Participants temporarily unable to swallow tablets instead
received beta-blockers via a nasogastric tube. Participants
were also permitted to receive supplemental intravenous
metoprolol at the discretion of their physicians. Other
aspects of clinical care were left to the discretion of the
participants’ physicians, aside from a restriction on using
open-label clonidine.
Data collection and outcomes
At the time of recruitment, we documented information on
age, sex, height, weight, blood pressure, heart rate,
comorbidities, medications, and serum creatinine
concentration. Perioperative cardiac risk was estimated
using the Revised Cardiac Risk Index (RCRI).18 Following
surgery, information was collected on surgical procedure,
anesthetic type, postoperative heart rate, and postoperative
blood pressure. We measured heart rate and blood pressure
every 15 min in the postanesthetic care unit (PACU) and then
every eight hours until postoperative day three or hospital
discharge (whichever occurred earlier). If several
Feasibility trial of perioperative clonidine 997
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measurements were taken within an eight-hour interval, the
lowest heart rate and blood pressure values were recorded.
Electrocardiograms (ECG) and troponin assays were
performed in the PACU at eight hours after surgery and then
once daily until the third postoperative day or until hospital
discharge (whichever occurred earlier). The participating
centres used standard (i.e., not high-sensitivity) troponin I
(Toronto General Hospital, Vancouver General Hospital) or
troponin T (Victoria Hospital) assays. We captured the
following clinical outcomes: mortality, MI, myocardial
injury (troponin concentration exceeding the threshold at
which the coefficient of variation for the assay was 10%),
non-fatal cardiac arrest, heart failure, and acute stroke.
Participant follow-up occurred daily while in hospital and
then by phone call at 30 days after surgery. Myocardial
infarction was defined as myocardial injury in combination
with clinical symptoms of ischemia, typical ECG changes,
coronary artery intervention, or presumed new changes on
echocardiography or radionuclide imaging.19 Two reviewers
blinded to treatment group adjudicated all diagnoses of MI.
Disagreements were resolved by consensus or a third blinded
reviewer. Safety outcomes included premature
discontinuation of the study drug, clinically significant
hypotension (postoperative systolic blood pressure \ 90
mmHg requiring a vasopressor or inotropic agent, study drug
discontinuation, or intra-aortic balloon pump), and clinically
significant bradycardia (postoperative bradycardia requiring
a pacemaker, sympathomimetic agent, atropine, or study
drug discontinuation). Decisions to discontinue the study
drug to address perceived complications of clonidine (e.g.,
hypotension) that were not responsive to usual interventions
(e.g., adjustment of epidural infusion) were left at the
discretion of individual responsible physicians.
Sample size and criteria for assessing feasibility
To have sufficient statistical power for detecting a plausible
reduction in postoperative cardiac events, a full-scale RCT
of perioperative clonidine will require a large sample size.
For example, if the rate of non-fatal MI or death in the
control arm is assumed to be 6%,20 7,204 participants are
required to detect a 25% relative risk reduction (two-sided
alpha of 0.05, 80% power, and continuity correction).
The purpose of this pilot study was to assess the
feasibility of conducting such a large multicentre trial in
intermediate-to high-risk surgical patients receiving
chronic beta-blocker therapy. Our primary objective was
to determine whether each centre could quickly reach a
recruitment rate of approximately four participants per
month and sustain the rate for 12 months. Based on this
objective, the planned sample size was 55 participants at
each site (i.e., 165 participants for the entire study). We
considered feasibility to be demonstrated if each centre
could recruit 50 participants within 12-18 months after an
initial run-in period to recruit the first five participants at
each site. If these 50 participants could be recruited within
12 months, we estimated that a larger multicentre trial with
recruitment of three years’ duration would involve
approximately 48 participating centres of similar size. If
18 months were required instead, 73 participating centres
would have to be involved. Previous experience with the
POISE-1 trial indicated that this degree of collaboration
was feasible.20 We anticipated that the number of required
centres could be further reduced if a future multicentre trial
also included patients not receiving chronic beta-blockade.
In addition to assessing recruitment rates, we qualitatively
reviewed safety outcomes and study drug withdrawals
related to the clonidine regimen.
Analyses
All analyses were performed on an intention-to-treat basis
using Stata version 13 (StataCorp, College Station, TX,
USA) and the R statistical language.A We reported
continuous data as means with standard deviations or with
interquartile ranges if the data were skewed. Categorical data
were reported as absolute numbers and percentages. Since
this feasibility study did not have statistical power to detect
clinically meaningful differences, we did not statistically test
for differences between groups.21 Instead, we estimated
between-group differences and 95% confidence intervals
(CI) for those differences. Multivariable linear regression
modelling was used to calculate the average difference over
time (with associated 95% CI) in systolic blood pressure
measurements following PACU discharge, while adjusting
for any differences in baseline preoperative blood pressure.
The model used generalized estimating equations to account
for correlation of repeated measurements within individual
participants. Similar methods were used to calculate average
differences in heart rate measurements following PACU
discharge.
Results
There were 168 participants randomized to clonidine
(n = 82) or placebo (n = 86). One patient in each group
did not undergo surgery (Fig. 1). Due to incremental
availability of funding, recruitment at the Toronto General
Hospital (June 2006 to November 2007), Vancouver
General Hospital (January 2008 to August 2009), and
A The R Project for Statistical Computing. R. A language and
environment for statistical computing. (Available from URL: http://
www.R-project.org). Vienna, Austria: R Foundation for Statistical
Computing; 2013 (accessed July 2014).
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Victoria Hospital (September 2007 to November 2008)
occurred in overlapping time periods with different start
dates.
The preoperative characteristics of the participants are
presented in Table 1. Overall, 71% of participants had
RCRI scores of one or two, while 17% had scores of three
or greater. There were some moderately large imbalances
between treatment arms, as would be expected in a
relatively small RCT.22
Recruitment of patients to this pilot RCT proved to be
feasible. Following the recruitment of the first five
participants at each site, the average time to recruit the
subsequent 50 participants was 14.3 months. The times
required at the three sites were 11.6, 12.8, and 18.5 months.
Trends in cumulative recruitment are presented in Fig. 4
(available as Electronic Supplemental Material). The
clonidine protocol used in this study was reasonably
tolerated, with six patients (7%) needing to be withdrawn
from clonidine therapy and four (5%) withdrawn in the
placebo arm. The postoperative hemodynamic status of the
study arms is presented in Table 2. Episodes of
postoperative systolic blood pressure \ 90 mmHg were
common, occurring in 25% (n = 42) of all participants and
24% (n = 21) of individuals in the control arm. Despite all
participants receiving chronic beta-blockade, episodes of
postoperative tachycardia were also frequent, with 40%
(n = 67) of all participants having episodes of heart rate[
90 beatsmin-1. Following PACU discharge, the mean
heart rate (Fig. 2) in the clonidine arm was 0.4 beatsmin-1
lower (95% CI, 4.8 lower to 3.9 higher). During this same
period, the mean systolic blood pressure in the clonidine
arm (Fig. 3) was 5.8 mmHg lower (95% CI, 11.0 lower to
0.7 lower).
Rates of postoperative events in the study arms are
presented in Table 3. Within the overall sample, 11%
(n = 18) of participants suffered postoperative MI and
16% (n = 27) suffered myocardial injury. By comparison,
the overall risk of 30-day mortality was 1% (n = 2).
Discussion
This pilot RCT at three large Canadian hospitals supported
the feasibility of a full-scale trial of perioperative
clonidine, for several reasons.
First, the overall recruitment rate of intermediate- to
high-risk patients receiving chronic beta-blockade met the
study threshold for determining feasibility, with each
centre recruiting slightly fewer than four participants per
month. While one centre did exceed the maximum 18-
month recruitment period by two weeks, this short delay
was due to unforeseen circumstances necessitating a
temporary halt to recruitment as opposed to inadequate
recruitment rates while the study was active. These findings
therefore support the feasibility of successfully completing
a full-scale trial of perioperative clonidine within a
reasonable time period. Second, the results support the
safety and tolerability of our perioperative clonidine
regimen. Based on qualitative feedback from research
Fig. 1 Flow of study
participants through the trial
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personnel, the regimen was simple to administer, monitor,
and follow up. The rate of active study drug
discontinuation was 7%, which is lower than rates
observed in RCTs of perioperative beta-blockade such as
the POISE-1 and DIPOM trials.20,23 In addition, there were
no early suggestions of safety concerns related to the
clonidine regimen. For example, rates of significant
hypotension in the clonidine and placebo arms were
qualitatively similar to rates observed in the placebo arm
of the POISE-1 trial.20 Third, the study inclusion criteria
successfully identified patients at intermediate- to high-risk





Age (yr), mean (SD) 70 (8) 72 (8)
Female sex 22 (27%) 28 (33%)
Height (cm), mean (SD) 168 (8) 169 (10)
Weight (kg), mean (SD) 84 (15) 85 (19)
Blood pressure
Systolic (mmHg), mean (SD) 136 (17) 133 (19)
Diastolic (mmHg), mean (SD) 76 (11) 76 (11)
Heart rate (beatsmin-1), mean (SD) 66 (11) 67 (13)
Comorbid Disease
Angina 16 (20%) 13 (15%)
Previous myocardial infarction 33 (40%) 31 (36%)
Previous stroke or transient ischemic attack 11 (13%) 13 (15%)
History of heart failure 8 (10%) 3 (4%)
Diabetes mellitus 20 (24%) 28 (33%)
Hypertension 71 (87%) 71 (83%)
Renal insufficiency
Dialysis-dependence 4 (5%) 2 (2%)
Moderate-to-severe renal insufficiency* 28 (34%) 26 (30%)
Current smoker 13 (16%) 12 (14%)
Revised Cardiac Risk Index
0 points 11 (13%) 9 (11%)
1 point 30 (37%) 34 (40%)
2 points 28 (34%) 28 (33%)
3 points 10 (12%) 10 (12%)
C 4 points 3 (4%) 5 (6%)
Medications
Beta-blocker
Metoprolol 42 (51%) 39 (45%)
Atenolol 29 (35%) 29 (34%)
Bisoprolol 6 (7%) 10 (12%)
Other beta-blocker 5 (6%) 8 (9%)
Calcium channel blocker 29 (35%) 31 (36%)
Dihydropyridine 23 (28%) 25 (29%)
Non-dihydropyridine 6 (7%) 6 (7%)
Renin-angiotensin-system inhibitor 54 (66%) 58 (67%)
ACE-inhibitor 46 (56%) 51 (59%)
ARB 12 (15%) 9 (11%)
ACE-inhibitor and ARB 4 (5%) 2 (2%)
Diuretic 21 (26%) 26 (30%)
Statin 62 (76%) 63 (73%)
Acetylsalicylic acid 47 (57%) 38 (44%)
Clopidogrel 9 (11%) 10 (12%)
Surgical procedure
Intraperitoneal 28 (34%) 26 (30%)
Intrathoracic 9 (11.0%) 14 (16%)






Major orthopedic 16 (20%) 18 (21%)
Other 4 (5%) 6 (7%)
Anesthetic technique
General anesthesia alone 52 (63%) 35 (41%)
Neuraxial anesthesia alone 14 (17%) 17 (20%)
Combined general and neuraxial anesthesia 15 (18%) 33 (38%)
Other regional nerve blocks alone 1 (1%) 1 (1%)
ACE = angiotensin-converting enzyme; ARB = angiotensin
receptor blocker; SD = standard deviation
* Dialysis-dependence or estimated glomerular filtration rate \ 60
mLmin-1 1.73m-2







Systolic blood pressure (mmHg),
mean (SD)
129 (23) 137 (23)
Diastolic blood pressure (mmHg),
mean (SD)
67 (14) 69 (13)
Heart rate (beatsmin-1), mean (SD) 73 (15) 73 (16)
Discharge
Systolic blood pressure (mmHg),
mean (SD)
124 (24) 128 (24)
Diastolic blood pressure (mmHg),
mean (SD)
63 (13) 67 (15)
Heart rate (beatsmin-1), mean (SD) 67 (15) 68 (14)
Postoperative Hemodynamic Episodes
Any episode of systolic blood pressure
\ 90 mmHg
21 (26%) 21 (24%)
Any episode of heart rate \ 50
beatsmin-1
8 (10%) 6 (7%)
Any episode of heart rate [ 90
beatsmin-1
27 (33%) 40 (47%)
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of perioperative cardiac complications. Approximately
11% of patients suffered perioperative MI, which is
higher than rates observed in the POISE-1 trial.20
Overall, the observed rates of participant recruitment and
outcome events, in combination with initial suggestions of
safety and tolerability, point to the feasibility of employing
our proposed perioperative regimen of oral and transdermal
clonidine in a full-scale definitive RCT.
Fig. 2 Trends in postoperative heart rate over time in the clonidine
and placebo arms. Heart rate was measured at the time of study
recruitment (i.e., baseline measurement in the preoperative
assessment clinic) and over the first 72 hr after surgery. Each
participant’s heart rate was measured at least every eight hours
postoperatively (i.e., three measurements per day as denoted on the
x-axis). The lowest measured values within each interval are
presented in this figure. Boxplots are used to represent the
distribution of heart rate at each time point. The box extends from
the 25th to 75th percentile, while the thick horizontal line within each
box represents the median value. The whisker bars denote the
minimum and maximum values
Fig. 3 Trends in postoperative systolic blood pressure over time in
the clonidine and placebo arms. Blood pressure was measured at the
time of study recruitment (i.e., baseline measurement in the
preoperative assessment clinic) and over the first 72 hr after
surgery. Each participant’s blood pressures was measured at least
every eight hours postoperatively (i.e., three measurements per day as
denoted on the x-axis). The lowest measured values within each
interval are presented in this figure. Boxplots are used to represent the
distribution of blood pressure at each time point. The box extends
from the 25th to 75th percentile, while the thick horizontal line within
each box represents the median value. The whisker bars denote the
minimum and maximum values
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Aside from confirming the feasibility of a full-scale
RCT of perioperative clonidine, several other aspects of
our results merit discussion. First, despite all patients
receiving beta-blockade and the presence of protocols to
continue these drugs in the perioperative period, inadequate
control of heart rate occurred frequently, with almost 40%
of participants experiencing a heart rate[90 beatsmin-1.
This observation points to the difficulties with achieving
adequate control of heart rate with beta-blockade. Notably,
previous RCTs of perioperative beta-blockade have also
observed a persistently high heart rate in participants
receiving active treatment. For example, in the DIPOM
trial, the heart rate among participants randomized to
receive metoprolol ranged from 40-120 beatsmin-1 on the
first day after surgery.23 Second, perioperative hypotension
also occurred frequently, with more than 25% of all
participants experiencing a systolic blood pressure \ 90
mmHg during their hospitalization. Notably, only half of
these cases were clinically significant, in that the episode of
hypotension necessitated pharmacologic intervention or
withdrawal of the study drug. Nonetheless, this observation
points to the frequency of perioperative hypotension during
usual clinical practice at tertiary-care Canadian medical
centres. Third, this study was not designed to facilitate
formal statistical comparison between the rates of adverse
events in the study arms. Stated otherwise, the sample size
provides insufficient statistical power to make these
comparisons.
Fourth, this feasibility study should now be interpreted in
light of the POISE-2 trial, which was published during the peer
review process for our present paper.24 The POISE-2 trial
assessed clonidine and acetylsalicylic acid in a factorial
fashion for preventing perioperative cardiac complications in
10,010 intermediate- to high-risk patients.24 It found that a
clonidine regimen very similar to that used in the EPIC trial
did not prevent 30-day mortality (risk difference 0.02%; 95%
CI, -0.4 to 0.5) or MI (risk difference 0.7%; 95% CI, -0.3 to
1.6) but significantly increased rates of significant
hypotension (risk difference 10.5%; 95% CI, 8.6 to 12.5).
There was no evidence of subgroup effects in the 2,359 (24%)
participants concurrently using beta-blockers. Our feasibility
study was largely concordant with this full-scale multicentre
trial. The successful completion of the POISE-2 trial within 30
months without early termination for major safety concerns
supports our conclusions regarding feasible recruitment rates
and safety of the proposed clonidine regimen. Additionally,
the confidence limits for differences in rates of clinical events
(Table 3) overlap with the estimates from the POISE-2 trial.
While our original intent was to proceed to a full-scale RCT of
perioperative clonidine if the EPIC trial showed feasibility,
the negative results of the POISE-2 trial (in which several
EPIC trial investigators participated) now indicates that a
separate full-scale trial, while feasible, is likely not needed.
Stated otherwise, there now exists strong evidence that
clonidine does not prevent perioperative cardiovascular
complications.
Conclusions
This multicentre pilot RCT confirmed the feasibility, safety,
and tolerability of a full-scale trial of perioperative oral and
transdermal clonidine for reducing perioperative cardiac risk
during major non-cardiac surgery. Consistent with this
Table 3 Postoperative clinical events
Clonidine n = 82 Placebo n = 86 Risk Difference (95% CI)
Myocardial infarction 12 (15%) 6 (7%) 7.6% (-1.8 to 17.8)
Non-fatal MI 12 (15%) 5 (6%) 8.8% (-0.4 to 18.9)
Elevated cardiac biomarker* 15 (18%) 12 (14%) 4.3% (-7.0 to 15.9)
Non-fatal cardiac arrest 3 (4%) 1 (1%) 2.5% (-3.0 to 9.2)
All-cause death 0 (0%) 2 (2%) -2.3% (-8.1 to 2.2)
Non-fatal MI or death 12 (15%) 7 (8%) 6.5% (-3.3 to 16.8)
Heart failure 3 (4%) 1 (1%) 2.5% (-3.0 to 9.2)
Acute stroke 0 (0%) 0 (0%) NA
Premature study drug discontinuation 6 (7%) 4 (5%) 2.7% (-5.1 to 11.1)
Clinically significant hypotension 7 (10%) 6 (7%) 1.6% (-7.1 to 10.6)
Clinically significant bradycardia 1 (1%) 0 (0%) 1.2% (-3.4 to 6.3)
CI = confidence interval; MI = myocardial infarction; NA = not applicable
* Troponin I or troponin T
 Defined as postoperative systolic blood pressure\90 mmHg necessitating study drug withdrawal, vasoactive medication administration, or
intra-aortic balloon pump support
 Defined as postoperative bradycardia requiring treatment with a pacemaker, sympathomimetic agent, atropine, or study drug withdrawal
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interpretation, the large POISE-2 trial used a very similar
perioperative regimen and successfully completed
recruitment, albeit in both users and non-users of chronic
beta-blockade. While the present study has shown feasibility
of a full-scale trial of perioperative clonidine, the negative
results of the POISE-2 trial indicate that such a separate full-
scale RCT, while feasible, is likely not needed.
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